FDA、膵臓がん治験薬の使用拡大を承認
.govという拡張子は、それが公式ウェブサイトであることを示しています。連邦政府のウェブサイトは通常、.govまたは.milで終わります。機密情報を共有する前に、アクセスしているウェブサイトが…
記事本文
FDA is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.
よくある質問
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
